Accordingly, in the same cohort, high HER2 expression in tumors, defined according to the median HER2 value as cut-off (log2 expression value = 10.37), was not significantly associated with any clinicopathological features (Table S1) and was related to a significantly better disease-free survival (DFS) probability than low HER2 expression in the entire cohort (Figure 1c) and in the tumor ER expression analysis (Figure 1d,e). Here, ERBB2 is linked to neoplasm.